Skip to main content
Premium Trial:

Request an Annual Quote

ZenBio Licenses Metabolic Cell Line from Harvard

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ZenBio today said that it has licensed rights from Harvard University to become a commercial source for the murine 3T3-L1 cell line for use in metabolic research.

The cell line is derived from 3T3 cells and is used in research on adipose tissue, making it popular for metabolic disease research studies, said the Research Triangle park, NC-based firm. It added that the cell line is recognized as a "very well-characterized, consistent in vitro system, and has served as the basis for a wide range of published studies."

ZenBio will offer the cell lines in low-passage cryopreserved and cultured forms, and it will also offer contract research services tailored to the 3T3-L1 in vitro system. Those services will include assay development, compound screening, conditioned media delivery, gene-expression profiling and further 3T3-L1 characterization. ZenBio also plans to offer metabolic research kits to measure various outputs from 3T3-L1 assays.

Terms of the license were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.